Datapoint: Dupixent Scores First-in-Class EoE Nod

Sanofi and Regeneron’s Dupixent last week became the first drug approved to treat eosinophilic esophagitis (EoE), a rare, progressive disease that causes severe inflammation of the esophagus. The FDA’s decision came more than two months before Dupixent’s original priority review date. The interleukin inhibitor was first approved in 2017, as a treatment for atopic dermatitis. For the treatment of atopic dermatitis, Dupixent holds covered or better status for 89% of all insured lives under the pharmacy benefit. 39% of insured lives have preferred access to Dupixent, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 5/23/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 23

Datapoint: Skyrizi Scores Crohn’s Disease Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 22

Datapoint: Merck-Seagen Deal Could Be in the Works

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 21

Datapoint: Centene Settles New Mexico Medicaid Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today